High Altitude Pulmonary Hypertension Clinical Trial
Official title:
The Impact of Hypoxia on Patients With Precapillary Pulmonary Hypertension and Treatment of Adverse Effects
The impact of a sojourn at 2500 m of high altitude for 26-30 h on constant work-rate exercise test time in patients with precapillary pulmonary hypertension
Patients with pulmonary hypertension will perform a constant work-rate exercise test at low altitude (450m) and at high altitude 2500m in a randomized-cross-over sequence protocol. The constant work-rate exercise test time and other measures will be assessed ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05264324 -
Maximal Exercise Capacity at 2500 m of High Altitude
|
N/A | |
Completed |
NCT05112172 -
Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m
|
N/A | |
Completed |
NCT05089487 -
Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension
|
N/A | |
Completed |
NCT05107700 -
Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m
|
N/A | |
Completed |
NCT03165656 -
Right Ventricular Function at Rest in Highlanders/Lowlanders
|
||
Completed |
NCT03165019 -
Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
|
||
Completed |
NCT03165032 -
Right Ventricular Function During Exercise in Highlanders/Lowlanders
|
||
Completed |
NCT03172429 -
Cerebral Tissue Oxygenation in Highlanders/Lowlanders
|
||
Completed |
NCT01566565 -
The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension
|
Phase 1 | |
Completed |
NCT01621061 -
Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders
|
N/A | |
Completed |
NCT01530464 -
The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers
|
Phase 1 |